<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-three patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were retrospectively analyzed for its prognostic factors </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the relationship of the clinical, biochemical, and hematological data, as well as colony-forming unit myeloid (CFU-C) culture, Bournemouth score, modified Bournemouth score, and modified Dutcher score to the prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>The median age was 65 years </plain></SENT>
<SENT sid="3" pm="."><plain>Eighteen patients had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 4 had <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 15 had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 2 had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t), and 4 had <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL) </plain></SENT>
<SENT sid="4" pm="."><plain>The median survival of <z:hpo ids='HP_0000001'>all</z:hpo> patients was 482 days </plain></SENT>
<SENT sid="5" pm="."><plain>The median survival for each subtype was as follows: RA, 628 days; CMMoL, 350 days; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 240 days; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, 90 days </plain></SENT>
<SENT sid="6" pm="."><plain>For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, no data have yet been obtained, because only one out of 4 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> has died </plain></SENT>
<SENT sid="7" pm="."><plain>We subdivided <z:hpo ids='HP_0000001'>all</z:hpo> patients into two groups: one group included patients with RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> and the other group included patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t or CMMoL </plain></SENT>
<SENT sid="8" pm="."><plain>The former group had a median survival of 677 days and the latter group 240 days, p = 0.0035 </plain></SENT>
<SENT sid="9" pm="."><plain>In the former group, 3 out of 22 patients (13.6%) developed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), as compared to 8 out of 21 patients (38.1%) in the latter group, p = 0.0661 </plain></SENT>
<SENT sid="10" pm="."><plain>Twenty-five of the 43 patients died: 10 from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 15 from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and/or <z:mp ids='MP_0001914'>bleeding</z:mp>.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>